Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Blood (2024) 144 (Supplement 1): 3446.

https://doi.org/10.1182/blood-2024-198872

Published: 2024

Journal Articles

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Daniel J. Landsburg, Michael Heim, Amy Moskop, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini, Matthew J Frigault

Blood (2023) 142 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2023-179387

Published: 2023

Journal Articles

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 108.

https://doi.org/10.1182/blood-2023-180858

Published: 2023

Journal Articles

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with T-Cell Malignancies: Final Results of a Phase I/II Trial

Blood (2023) 142 (Supplement 1): 184.

https://doi.org/10.1182/blood-2023-190213

Published: 2023

Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Blood (2023) 142 (Supplement 1): 1761.

https://doi.org/10.1182/blood-2023-173873

Published: 2023

Journal Articles

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Mazyar Shadman, Matthew J Frigault, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Daniel J. Landsburg, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini

Blood (2023) 142 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2023-180233

Published: 2023

Journal Articles

Running the tank to empty: how far can the CAR go?

Sumithira Vasu, Samantha M. Jaglowski

Blood (2019) 133 (15): 1617–1618.

https://doi.org/10.1182/blood-2019-02-900761

Published: 2019

Journal Articles

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Blood (2017) 130 (Supplement 1): 1932.

https://doi.org/10.1182/blood.V130.Suppl_1.1932.1932

Published: 2017

Journal Articles

Road trip to remission with CARs

Samantha M. Jaglowski

Blood (2017) 130 (21): 2240.

https://doi.org/10.1182/blood-2017-10-808584

Published: 2017

Journal Articles

Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)

Hassan Issa, MD, Amy S. Ruppert, MAS, Patrick Elder, M.S, Craig Hofmeister, Don M Benson, MD PhD, Sam Penza, MD, Leslie A. Andritsos, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, William Blum, MD, Samantha M. Jaglowski, MD, Steven M. Devine, MD, Yvonne A Efebera, MD

Blood (2015) 126 (23): 4328.

https://doi.org/10.1182/blood.V126.23.4328.4328

Published: 2015

Journal Articles

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

Blood (2015) 126 (7): 842–850.

https://doi.org/10.1182/blood-2014-12-617522

Published: 2015

Includes: Supplemental data

Journal Articles

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Ta-Ming Liu, Jennifer A. Woyach, Yiming Zhong, Arletta Lozanski, Gerard Lozanski, Shuai Dong, Ethan Strattan, Amy Lehman, Xiaoli Zhang, Jeffrey A. Jones, Joseph Flynn, Leslie A. Andritsos, Kami Maddocks, Samantha M. Jaglowski, Kristie A. Blum, John C. Byrd, Jason A. Dubovsky, Amy J. Johnson

Blood (2015) 126 (1): 61–68.

https://doi.org/10.1182/blood-2015-02-626846

Published: 2015

Includes: Supplemental data

Journal Articles

Transplant for CLL: still an option?

Samantha M. Jaglowski

Blood (2014) 124 (26): 3835–3836.

https://doi.org/10.1182/blood-2014-10-606871

Published: 2014

Journal Articles

Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT)

Yvonne A Efebera, MD, Susan Geyer, PhD, Anissa Bingman, M.S., Patrick Elder, MS, Rhonda Kitzler, BS, Kevin Coombes, PhD, Carrie Hennelly, MA, Katie Cortright, BS, Leslie A. Andritsos, MD, Samantha M. Jaglowski, MD MPH, Sumithira Vasu, MBBS, William Blum, MD, Rebecca B. Klisovic, MD, Sam Penza, MD, Craig C Hofmeister, MD MPH, Don M Benson, MD PhD, Gerard Lozanski, MD, Steven M. Devine, MD

Blood (2014) 124 (21): 3929.

https://doi.org/10.1182/blood.V124.21.3929.3929

Published: 2014

Journal Articles

A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)

Beth Christian, MD, Lai Wei, Jennifer Sexton, Samantha M. Jaglowski, MD MPH, Steven M. Devine, MD, Todd A. Fehniger, MD PhD, Nina Wagner-Johnston, Nancy L. Bartlett, MD, Kristie A. Blum, MD

Blood (2014) 124 (21): 3099.

https://doi.org/10.1182/blood.V124.21.3099.3099

Published: 2014

Journal Articles

A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Beth Christian, MD, Joseph M Flynn, DO, MPH, Samantha M. Jaglowski, MD MPH, Kristie A. Blum, MD

Blood (2014) 124 (21): 3082.

https://doi.org/10.1182/blood.V124.21.3082.3082

Published: 2014

Journal Articles

Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Yvonne A Efebera, MD, Susan Geyer, PhD, Anissa Bingman, M.S., Rhonda Kitzler, BS, Patrick Elder, MS, Leslie A. Andritsos, MD, Samantha M. Jaglowski, MD MPH, Sumithira Vasu, MBBS, William Blum, MD, Rebecca B. Klisovic, MD, Sam Penza, MD, Kevin Coombes, PhD, Craig C Hofmeister, MD MPH, Don Benson, MD PhD, Steven M. Devine, MD, Gerard Lozanski, MD

Blood (2014) 124 (21): 1166.

https://doi.org/10.1182/blood.V124.21.1166.1166

Published: 2014

Journal Articles

A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies

Bradley M. Haverkos, MD MPH, Katie Cortright, BS, Leslie A. Andritsos, MD, William Blum, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, David M Goldenberg, ScD, MD, William A Wegener, MD PhD, Steven M. Devine, MD, Samantha M. Jaglowski, MD MPH

Blood (2014) 124 (21): 1168.

https://doi.org/10.1182/blood.V124.21.1168.1168

Published: 2014

Journal Articles

Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation

Sumithira Vasu, MBBS, Anissa Bingman, M.S., Susan Geyer, PhD, Patrick Elder, Rhonda Kitzler, BS, Hillary Bradbury, Lynn Odonnell, William Blum, MD, Samantha M. Jaglowski, MD MPH, Leslie A. Andritsos, MD, Rebecca B. Klisovic, MD, Sam Penza, MD, Yvonne A Efebera, MD, Craig C. Hofmeister, MD, Don M. Benson, MD PhD, Natarajan Muthusamy, DVM, PhD, Gerard Lozanski, MD, Steven M. Devine, MD

Blood (2014) 124 (21): 2494.

https://doi.org/10.1182/blood.V124.21.2494.2494

Published: 2014

Journal Articles

Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype

Deborah M Stephens, DO, Amy Stark, MAS, Jeffrey A. Jones, MD, MPH, Jennifer A. Woyach, MD, Kami Maddocks, Samantha M. Jaglowski, MD, MPH, Leslie A. Andritsos, MD, Joseph M. M. Flynn, DO, MPH, Michael R. Grever, MD, Gerard Lozanski, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, Ph.D, Nyla A. Heerema, PhD, John C. Byrd, MD

Blood (2013) 122 (21): 2872.

https://doi.org/10.1182/blood.V122.21.2872.2872

Published: 2013

NARROW

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with T-Cell Malignancies: Final Results of a Phase I/II Trial

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Running the tank to empty: how far can the CAR go?

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Road trip to remission with CARs

Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Transplant for CLL: still an option?

Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT)

A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)

A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)

Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies

Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation

Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only